These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 11897053)
21. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic. Ma B; Chai S; Li N; To KK; Kan WL; Yang D; Lin G Int J Pharm; 2012 Mar; 424(1-2):33-9. PubMed ID: 22226881 [TBL] [Abstract][Full Text] [Related]
22. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Chen G; Teicher BA; Frei E Anticancer Res; 1996; 16(6B):3499-505. PubMed ID: 9042212 [TBL] [Abstract][Full Text] [Related]
23. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476 [TBL] [Abstract][Full Text] [Related]
24. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Mazzanti R; Croop JM; Gatmaitan Z; Budding M; Steiglitz K; Arceci R; Arias IM Oncol Res; 1992; 4(8-9):359-65. PubMed ID: 1362504 [TBL] [Abstract][Full Text] [Related]
25. Menadione serves as a substrate for P-glycoprotein: implication in chemosensitizing activity. Oh SJ; Han HK; Kang KW; Lee YJ; Lee MY Arch Pharm Res; 2013 Apr; 36(4):509-16. PubMed ID: 23435914 [TBL] [Abstract][Full Text] [Related]
26. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells. Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007 [TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein (Pgp) does not affect the cytotoxicity of flavonoids from Sophora flavescens, which also have no effects on Pgp action. Choi SU; Kim KH; Choi EJ; Park SH; Lee CO; Jung NP; Yoon SK; Ryu SY Anticancer Res; 1999; 19(3A):2035-40. PubMed ID: 10470145 [TBL] [Abstract][Full Text] [Related]
28. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Ferreira MJ; Duarte N; Gyémánt N; Radics R; Cherepnev G; Varga A; Molnár J Anticancer Res; 2006; 26(5A):3541-6. PubMed ID: 17094479 [TBL] [Abstract][Full Text] [Related]
29. Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells. Im YB; Ha I; Kang KW; Lee MY; Han HK Nutr Cancer; 2009; 61(4):538-43. PubMed ID: 19838926 [TBL] [Abstract][Full Text] [Related]
30. Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells. Su S; Cheng X; Wink M Phytomedicine; 2015 Feb; 22(2):301-7. PubMed ID: 25765837 [TBL] [Abstract][Full Text] [Related]
31. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Shen X; Chen G; Zhu G; Fong WF Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827 [TBL] [Abstract][Full Text] [Related]
32. Multiwavelength videomicrofluorometric study of some human leukemic lymphoblasts: effect of adriamycin on some biological parameter. Rocchi E; Vigo J; Viallet P; Salmon JM Anticancer Res; 1998; 18(2A):1091-7. PubMed ID: 9615771 [TBL] [Abstract][Full Text] [Related]
33. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852 [TBL] [Abstract][Full Text] [Related]
34. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Pourtier-Manzanedo A; Didier AD; Muller CD; Loor F Anticancer Drugs; 1992 Aug; 3(4):419-25. PubMed ID: 1421439 [TBL] [Abstract][Full Text] [Related]
35. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Choi CH; Kang G; Min YD Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527 [TBL] [Abstract][Full Text] [Related]
36. Reversal of multidrug resistance: lessons from clinical oncology. Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784 [TBL] [Abstract][Full Text] [Related]
37. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin. Gao A; Wang X; Xiang W; Liang H; Gao J; Yan Y J Pharm Pharmacol; 2010 Mar; 62(3):393-9. PubMed ID: 20487225 [TBL] [Abstract][Full Text] [Related]
38. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Brouty-Boyé D; Kolonias D; Wu CJ; Savaraj N; Lampidis TJ Cancer Res; 1995 Apr; 55(8):1633-8. PubMed ID: 7712466 [TBL] [Abstract][Full Text] [Related]
39. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. Elamanchili P; McEachern C; Burt H J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213 [TBL] [Abstract][Full Text] [Related]
40. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]